Interventions of Interest: Intensity modulated radiation therapy for prostate cancer Prostate cancer is the most common nondermatologic cancer in men. In 2006, approximately230,000 new patients in the United States were diagnosed with prostate cancer and 27,000 men died of the disease. The major treatment options for localized prostate cancer include external beam radiation therapy, brachytherapy, […]
Interventions of Interest: Brachytherapy and Proton beam therapy for prostate cancer. Prostate cancer is the second leading cause of cancer deaths and the seventh overall causeof death in men in the United States (Centers for Disease Control and Prevention, 2008).Given that most new cases are diagnosed at an early, localized stage, significant attentionhas been focused […]
ICER developed a report on Active Surveillance and Radical Prostatectomy for prostate cancer. Prostate cancer is the second leading cause of cancer deaths and the seventh overall causeof death in men in the United States (Centers for Disease Control and Prevention, 2008).Given that most new cases are diagnosed at an early, localized stage, significant attentionhas […]
Interventions of Interest: enzalutamide (Xtandi®, Astellas and Medivation) abiraterone acetate (Zytiga®, Janssen) apalutamide (Erleada™, Janssen). October 2018 Review ICER developed a report on anti-androgen drugs for high risk prostate cancer. The added costs of treating earlier stage disease with all therapies are aligned with their added clinical benefits for patients. For questions or additional information, […]
Intervention of interest: Proton beam therapy ICER completed a Technology Assessment of proton beam therapy (PBT) for the public meeting of the Washington State Health Care Authority Clinical Committee. ICER’s review found that PBT was superior to surgical treatment of tumors of the eye, and appears to be a safer alternative to conventional radiation in […]
Interventions of Interest: Due to the COVID-19 pandemic, we have decided to indefinitely postpone our public meeting on therapies for sickle cell disease (originally slated for March 26, 2020). Please refer to the sickle cell disease evidence report for our most updated findings. Date of review: March 2020 For questions, please contact info@icer.org View the […]
Interventions of Interest: Valbenazine (Ingrezza®, Neurocrine Biosciences, Inc) Deutetrabenazine (Austedo®, Teva) Tetrabenazine (Xenazine®, Ovation Pharmaceuticals) Tardive dyskinesia is a serious and disabling movement disorder that affects individuals treated with antipsychotic agents for a variety of mental health conditions. Though prevention and treatment primarily focus on stopping or changing the offending antipsychotic agent, for some individuals […]
Interventions of Interest: oral semaglutide (Rybelsus®, Novo Nordisk) liraglutide (Victoza®, Novo Nordisk) sitagliptin (Januvia®, Merck) empagliflozin (Jardiance®, Boehringer Ingelheim). Type 2 diabetes mellitus (T2DM) is a condition where cells do not respond adequately to insulin and so there are high glucose (sugar) levels. In the United States approximately 30 million individuals have diabetes mellitus (DM), […]
ICER developed a report assessing the comparative clinical effectiveness and value of voretigene neparvovec (Luxturna®, Spark Therapeutics), a potentially one-time gene therapy for vision loss associated with biallelic RPE65-mediated retinal disease. Voretigene neparvovec is the first gene therapy to be approved by the US Food and Drug Administration (FDA). The appraisal committee vote revealed differences […]
2014 Interventions of Interest: Sulfonylureas Insulin Dipeptidyl peptidase-4 (DPP-4) inhibitors Glucagon-like peptide-1 (GLP-1) receptor agonists Continuous blood glucose monitoring The management of type 2 diabetes has received significant attention over the past decade due to the increasing prevalence of this condition and the rise in costs associated with its treatment. Approximately 29 million Americans have […]